Click Here to Download the [WHITE PAPER] Right-to-Try or Right-to-Ask: Understanding Right-to-Try and FDA’s Expanded Access Programs
| This week's FierceBiotech is brought to you by Rho.
Trouble viewing? Click here. |
| | | | | | | Hi Colleague, Right-to-Try has been in the news a lot recently, but what does it actually mean for product sponsors? This white paper explores both Right-to-Try legislation and existing Expanded Access Programs, including:
|
| | Understanding sponsor responsibilities under these programs and when products may be eligible for these programs Evaluating options such as treatment protocols, treatment INDs, and emergency use Discussing development risks associated with participation in these programs |
|
|
|
| Download this white paper |
| | |
| | |
|
|
| |
| Want to reach 150,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.
About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe. Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400
Washington, DC 20036 |
